Hospital Injectable Products · LP-180
Ceftriaxone Powder for injection
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-180Hospital Injectable Products
- Generic identity
- CeftriaxonePowder for injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-180
- Generic identity
- Ceftriaxone
- Presentation
- Powder for injection
- Catalogue strength
- 500 mg vial; 1 g vial; 2 g vial
- Catalogue pack
- Vial; carton 10 vials
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: ceftriaxone.
- Dosage form: powder for injection.
- Proposed vial strengths: 500 mg, 1 g and 2 g.
- General proposed pack: vial; carton of 10 vials.
Layer 02 · Unresolved product-specific fields
- Exact salt/formulation and sterile finished-product specification.
- Diluent, reconstitution volume/concentration, route, infusion/injection instructions and compatibility.
- Approved indications/dosing and complete warnings.
- Storage, stability after preparation, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 500 mg vial | Powder for injection | Vial | General carton of 10 | No product-specific reconstitution or route instructions established. |
| B | 1 g vial | Powder for injection | Vial | General carton of 10 | No product-specific reconstitution or route instructions established. |
| C | 2 g vial | Powder for injection | Vial | General carton of 10 | No product-specific reconstitution or route instructions established. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Ceftriaxone is a cephalosporin antibiotic used for selected susceptible bacterial infections. It inhibits bacterial cell-wall synthesis and is supplied in parenteral formulations. Its clinical role depends on the suspected pathogen, infection site, patient age and relevant resistance patterns. A broad antibacterial spectrum does not mean it is appropriate for every fever, viral illness or community infection.
Clinical context and therapeutic role
Professional assessment establishes whether parenteral treatment is needed and uses cultures or other diagnostic results to refine therapy when appropriate. Patient age is especially important because neonatal restrictions and compatibility issues can differ from adult practice. The listed vial strengths are not prescribing guidance. External monographs may describe several presentations and indications; they do not establish the precise route, diluent or local authorization of the candidate.
Selected safety context
Important concerns include severe beta-lactam allergy, antibiotic-associated colitis, blood-cell reactions and neurological toxicity in susceptible patients. Ceftriaxone has critical compatibility restrictions with calcium-containing intravenous solutions, particularly in neonates. Prematurity and neonatal bilirubin-related risks require specific review. Biliary or urinary precipitation can also be clinically relevant. Product preparation and co-administration must follow the exact authorized label and local safety procedures.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The record lists powder-for-injection vials. Some diluents can restrict the permitted administration route, so no diluent or route can be assumed. Verify calcium compatibility, reconstitution instructions, solution characteristics and stability for the actual presentation.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Review patient age, infection diagnosis, microbiology, allergy, organ function and concurrent calcium-containing therapy. Verify the exact vial, diluent and route before administration.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Sterile finished-product specification and container closure.
Approved injectable label/leaflet with reconstitution, route and compatibility instructions.
Stability/hold-time data.
Registration, manufacturing-site, GMP/scope and release evidence as applicable.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Ceftriaxone — ingredient/formulation referenceArchived source classification: government-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-180.
Professional enquiries
Request product-specific evidence for LP-180.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.